SLC5A2 and heart failure: Therefore, the 2022 AHA/ACC/HFSA guidelines for the management of heart failure firstly recommends SGLT2 inhibitors as new therapeutic agents in Class IIA, the strongest class into the treatment recommendations for HFpEF patients [36].